X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
RANBAXY LABORATORIES LIMITED Quarterly Results - Equitymaster
 
RANBAXY LABORATORIES LIMITED  - Last 8 Quarters  (RANB)

Here are the latest quarterly results of Ranbaxy Lab. For more details, see the Ranbaxy Lab financial fact sheet and Ranbaxy Lab share price and chart. For a sector overview, read our pharmaceuticals sector report.
 Interim Results
No. of Months
Qtr. Ending
3
Mar-13
*
3
Jun-13
*
3
Sep-13
*
3
Dec-13
*
3
Mar-14
*
3
Jun-14
*
3
Sep-14
*
3
Dec-14
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m25,00626,83528,01628,94024,66824,26332,60526,188 
Other income Rs m624354261352237255174107 
Turnover Rs m25,63027,18928,27729,29224,90524,51732,77926,295 
Expenses Rs m23,09924,83826,02526,13523,16122,00323,81523,733 
Gross profit Rs m1,8481,9321,9342,6991,5732,2698,7852,395 
Depreciation Rs m7977631,3349159531,0741,019969 
Interest Rs m5251,5911,1151,2061,1361,4241,3731,469 
Profit before tax Rs m1,150-68-254931-279256,56764 
Tax Rs m3533115709811,099-568518,882 
Profit after tax Rs m797-379-824-51-1,377815,716-8,818 
Gross profit margin %7.47.26.99.36.49.426.99.1 
Effective tax rate %30.7-457.4-224.4105.4-394.4-220.713.013,880.2 
Net profit margin %3.2-1.4-2.9-0.2-5.60.317.5-33.7 
Diluted EPS Rs 1.9 -0.9 -1.9 -0.1 -3.2 0.2 13.4 -20.7  
Diluted EPS (TTM) Rs 12.6 5.5 -3.3 -1.1 -6.2 -5.1 10.2 -10.3  
 Subscriber Feature Our View Our View Our View   Our View        
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster



Today's Market

Sensex Finishes Firm; Realty Stocks Rise(Closing)

Indian share markets finished the trading day on a firm note as the country moved a step closer to implementing a nationwide goods and services tax (GST) from July.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Why Real Estate Prices are Going Down at a Slow Pace(Vivek Kaul's Diary)

Mar 23, 2017

Many investors have got anchored to a selling price which has got nothing to do with the current state of the real estate market

Why Mutual Fund Investors Should Not Worry About Market High. But...(Outside View)

Mar 22, 2017

PersonalFN provides a prudent investment strategy to invest in mutual funds as market scales a new high.

Bad Loans Inventory Bloats Up(Chart Of The Day)

Mar 18, 2017

This is why RBI's new strategy is ineffective to deal with bad debt menace.

More

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON RANBAXY LAB

RANBAXY LAB 5-YR ANALYSIS

Detailed Financial Information With Charts

COMPARE RANBAXY LAB WITH

MARKET STATS